Author

M. Murga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

O. Fernandez-Capetillo· 3 shared E. Fueyo-Marcos· 2 shared M. E. Anton· 2 shared M. Lafarga· 2 shared A. Corman· 1 shared A. G. Serrano· 1 shared B. Porebski· 1 shared B. Seashore-Ludlow· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

O. Fernandez-Capetillo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SETD8 inhibition targets cancer cells with increased rates of ribosome biogenesis

M. Murga, G. Lopez-Pernas, R. Soliva, E. Fueyo-Marcos, C. Amor, I. Faustino, M. Serna, A. G. Serrano, L. Diaz, S. Martinez, C. Blanco-Aparicio, M. E. Anton, B. Seashore-Ludlow, J. Pastor, R. Jafari, , O. Fernandez-Capetillo

This study identifies novel SETD8 inhibitors and shows their toxicity correlates with ribosome biogenesis regulators, suggesting a biomarker for targeted cancer therapy.

bioRxiv · Jun 11, 2024Cancer Biology

Discovery of a novel inhibitor of macropinocytosis with antiviral activity

B. Porebski, W. Christ, A. Corman, M. Haraldsson, M. Barz, L. Lidemalm, M. Haggblad, J. Illmain, S. Wright, M. Murga, J. Schlegel, E. Sezgin, G. Bhabha, V. M. Lauschke, M. Lafarga, , O. Fernandez-Capetillo

This study identifies virapinib, a novel inhibitor of macropinocytosis that blocks viral entry by SARS-CoV-2, Monkeypox virus, and TBEV without host cell toxicity.

bioRxiv · Oct 25, 2023Pharmacology & Toxicology

PD-L1ATTAC mice reveal the potential of targeting PD-L1 expressing cells in cancer therapy

E. Fueyo-Marcos, C. Fustero-Torre, G. Lopez, M. E. Anton, F. Al-Shahrour, O. Fernandez-Capetillo, M. Murga

The paper develops PD-L1ATTAC mice to study PD-L1-expressing cells' role in cancer and immunity, finding their elimination enhances antitumor immunity and worsens septic responses.

bioRxiv · Jul 22, 2022 · PreprintCancer Biology